Tags

Type your tag names separated by a space and hit enter

Parathyroid hormone-related protein and hypercalcemia.
Cancer. 1997 Oct 15; 80(8 Suppl):1564-71.C

Abstract

The discovery of parathyroid hormone-related protein (PTH-rP) arose from interest in the mechanisms by which certain cancers cause hypercalcemia without necessarily metastasizing to bone. The humoral hypercalcemia of malignancy (HHM) had for a long time been ascribed to inappropriate production of parathyroid hormone (PTH) by cancers. The amino-terminal portions of PTH-rP and PTH have essentially identical actions through a common receptor for PTH/PTH-rP: to elevate plasma calcium by promoting bone resorption and decreasing calcium excretion. Assays for plasma PTH-rP fail to detect protein convincingly in normal plasma, but measurable levels have been found in up to 100% of patients with HHM, in 75% of patients with breast carcinoma metastatic to bone, and in some hypercalcemic patients with miscellaneous cancers. Whereas PTH-rP clearly functions as a hormone in those cancers in which it is produced in excess, in normal circumstances it is produced locally in many tissues in which it is a paracrine effector. There appears to be little doubt that PTH-rP is the major mediator of hypercalcemia in patients with HHM, although it is possible that other factors (e.g., bone resorbing cytokines) also could contribute in some patients. In the case of breast carcinoma, another possible role arises for PTH-rP. The high incidence of PTH-rP production by primary breast carcinomas, elevated plasma levels in 60% of those with hypercalcemia and lytic metastases, and higher incidence of PTH-rP production in skeletal versus those with nonskeletal metastases have led to the hypothesis that PTH-rP might contribute to breast carcinoma growth in bone. Experimental evidence currently is available to support this hypothesis. The discovery of PTH-rP has contributed greatly to current understanding of the skeletal complications of cancer.

Authors+Show Affiliations

Rankin W
The University of Melbourne, Department of Medicine, St. Vincent's Hospital, Fitzroy, Victoria, Australia.
Grill V
No affiliation info available
Martin TJ
No affiliation info available

MeSH

AnimalsBone NeoplasmsBreast NeoplasmsFemaleHumansHypercalcemiaMaleMiceMice, NudeNeoplasm ProteinsNeoplasmsParathyroid HormoneParathyroid Hormone-Related ProteinProstatic NeoplasmsProteinsRNA, MessengerRats

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

9362423

Citation

Rankin, W, et al. "Parathyroid Hormone-related Protein and Hypercalcemia." Cancer, vol. 80, no. 8 Suppl, 1997, pp. 1564-71.
Rankin W, Grill V, Martin TJ. Parathyroid hormone-related protein and hypercalcemia. Cancer. 1997;80(8 Suppl):1564-71.
Rankin, W., Grill, V., & Martin, T. J. (1997). Parathyroid hormone-related protein and hypercalcemia. Cancer, 80(8 Suppl), 1564-71.
Rankin W, Grill V, Martin TJ. Parathyroid Hormone-related Protein and Hypercalcemia. Cancer. 1997 Oct 15;80(8 Suppl):1564-71. PubMed PMID: 9362423.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Parathyroid hormone-related protein and hypercalcemia. AU - Rankin,W, AU - Grill,V, AU - Martin,T J, PY - 1997/11/15/pubmed PY - 2000/6/20/medline PY - 1997/11/15/entrez SP - 1564 EP - 71 JF - Cancer JO - Cancer VL - 80 IS - 8 Suppl N2 - The discovery of parathyroid hormone-related protein (PTH-rP) arose from interest in the mechanisms by which certain cancers cause hypercalcemia without necessarily metastasizing to bone. The humoral hypercalcemia of malignancy (HHM) had for a long time been ascribed to inappropriate production of parathyroid hormone (PTH) by cancers. The amino-terminal portions of PTH-rP and PTH have essentially identical actions through a common receptor for PTH/PTH-rP: to elevate plasma calcium by promoting bone resorption and decreasing calcium excretion. Assays for plasma PTH-rP fail to detect protein convincingly in normal plasma, but measurable levels have been found in up to 100% of patients with HHM, in 75% of patients with breast carcinoma metastatic to bone, and in some hypercalcemic patients with miscellaneous cancers. Whereas PTH-rP clearly functions as a hormone in those cancers in which it is produced in excess, in normal circumstances it is produced locally in many tissues in which it is a paracrine effector. There appears to be little doubt that PTH-rP is the major mediator of hypercalcemia in patients with HHM, although it is possible that other factors (e.g., bone resorbing cytokines) also could contribute in some patients. In the case of breast carcinoma, another possible role arises for PTH-rP. The high incidence of PTH-rP production by primary breast carcinomas, elevated plasma levels in 60% of those with hypercalcemia and lytic metastases, and higher incidence of PTH-rP production in skeletal versus those with nonskeletal metastases have led to the hypothesis that PTH-rP might contribute to breast carcinoma growth in bone. Experimental evidence currently is available to support this hypothesis. The discovery of PTH-rP has contributed greatly to current understanding of the skeletal complications of cancer. SN - 0008-543X UR - https://www.unboundmedicine.com/medline/citation/9362423/Parathyroid_hormone_related_protein_and_hypercalcemia_ L2 - https://medlineplus.gov/bonecancer.html DB - PRIME DP - Unbound Medicine ER -